Table 1 Currently available agents against the IGF pathway evaluated in clinical trials for the treatment of HCC
Compound | Company | Mechanism of action | Phase of clinical development | Trial Status | Intervention | Type of Cancer |
|---|---|---|---|---|---|---|
MEDI-573 | MedImmune LLC | Fully Human mAb anti- IGF1 and –IGF2 | 1b/2 | Completed | In combination with sorafenib | Unresectable or metastatic HCC |
IMC-A12 | National Cancer Institute | Fully Recombinant Human mAb anti- IGF1R | 2 | Completed | Alone | Adult Primary, advanced, localized unresectable, recurrent HCC |
| Â | National Cancer Institute | Â | 1 | Active, not recruiting | In combination with sorafenib tosylate | Advanced HCC |
| Â | Eli Lilly and Company | Â | 2 | Active, not recruiting | In combination with sorafenib | Advanced HCC |
BIIB-022 | BiogenIdec | Human IgG4P nonglycosylated antibody anti-IGF1R | 1b | Completed | In combination with sorafenib | Advanced HCC |
AVE-1640 | Sanofi-Aventis | Humanized mAb anti- IGF1R | 1/2 | Completed | Alone and in combination with sorafenib and erlotinib | HCC not eligible for local treatment |
OSI-906 | AstellasPharmaInc | Small molecule inhibitor of IGF1R | 2 | Completed | Alone | With advanced HCC after failure of first-line treatment with sorafenib |